Want to join the conversation?
During 3Q15, $PFE's Global Oncology segment revenues increased 54% YoverY, primarily driven by continued strong momentum following the Feb. 2015 US launch of Ibrance for advanced breast cancer and stronger demand for Sutent, Xalkori and Inlyta in most markets.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.
$SPY can the rally continue? La Pen almost assured to lose makes me cautious about the results, not a place to panic. If 2400 is reached I'm selling my puts and going for broke. Happy hunting.